• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 31, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Scientists reveal details of antibodies that work against Zika virus

Bioengineer by Bioengineer
February 25, 2021
in Chemistry
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development

IMAGE

Credit: Image courtesy of Shannon Esswein.

ROCKVILLE, MD – The Zika outbreak of 2015 and 2016 is having lasting impacts on children whose mothers became infected with the virus while they were pregnant. Though the numbers of Zika virus infections have dropped, which scientists speculate may be due to herd immunity in some areas, there is still potential for future outbreaks. To prevent such outbreaks, scientists want to understand how the immune system recognizes Zika virus, in hopes of developing vaccines against it. Shannon Esswein, a graduate student, and Pamela Bjorkman, a professor, at the California Institute of Technology, have new insights on how the body’s antibodies attach to Zika virus. Esswein will present the work, which was published in PNAS, on Thursday, February 25 at the 65th Biophysical Society Annual Meeting.

Zika virus is a kind of flavivirus, and other flavivirus family members include dengue, West Nile, and yellow fever virus. To protect against these and other pathogens, “we have the ability to make a huge diversity of antibodies, and if we get infected or vaccinated, those antibodies recognize the pathogen,” Esswein said. But sometimes when the body mounts an immune response against a flavivirus, there is concern that this response could make the person sicker if they get infected a second time. Called antibody-dependent enhancement (ADE), this happens when the antibodies stick to the outside of the virus without blocking its ability to infect cells, which can inadvertently help the virus infect more cells by allowing it enter cells that the antibodies stick to.

In order to prevent ADE when creating a vaccine, it’s crucial for scientists to have a detailed understanding of how antibodies stick to a specific virus. This is especially important for flaviviruses, because antibodies that protect against one flavivirus may also stick to, but not protect against other flavivirus, increasing the risk of ADE. There is a concern that antibodies generated in response to a Zika virus vaccine could trigger ADE if someone were to be later infected with dengue or other flaviviruses.

To study the antibody response to Zika and other flavivirus, Esswein and Bjorkman looked at several antibodies from the blood of patients from Mexico and Brazil. To find antibodies that recognize flaviviruses, they used a piece of the outside of the virus, called the envelope domain III protein. Previous studies have shown the envelope domain III is an important target of protective antibodies that fight flavivirus infections.

The researchers studied how those antibodies changed over time as they mature and become better able to stick to Zika virus, and also how the antibodies cross-react with other flaviviruses, including the four types of dengue viruses. They found that the Zika antibodies also tightly stick to and defend against dengue type 1, and weakly stick to West Nile and dengue types 2 and 4. “The weak cross-reactivity of these antibodies doesn’t seem to defend against those flaviviruses, but also doesn’t induce ADE,” Esswein said, suggesting envelope domain III may be useful to make a vaccine that is safe. They also determined structures showing how two antibodies recognize Zika and West Nile envelope domain III.

Together, the team’s experiments show how the body mounts “a potent immune response to Zika virus,” says Esswein. Their insights into the antibodies involved in this immune response will help inform vaccine design strategy.

###

Media Contact
Leann Fox
[email protected]

Original Source

https://www.biophysics.org/news-room?ArtMID=802&ArticleID=10420&preview=true

Tags: Biomechanics/BiophysicsBiotechnologyChemistry/Physics/Materials SciencesCritical Care/Emergency MedicineEpidemiologyGenesImmunology/Allergies/AsthmaInfectious/Emerging DiseasesVaccines
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Researchers Discover Novel Energy Potential in Iron-Based Materials

October 31, 2025

UCSB Experimentalists Awarded Gordon and Betty Moore Foundation Grants to Propel New Insights and Innovations

October 30, 2025

Truly strange and thrilling: Quantum oscillations ripple through this science magazine headline

October 30, 2025

Mapping Proteome-wide Selectivity of Diverse Electrophiles

October 30, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1293 shares
    Share 516 Tweet 323
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    202 shares
    Share 81 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    136 shares
    Share 54 Tweet 34

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Assessing Assistance Needs in Home-Dwelling Seniors

On-Farm Trials Boost Grain Micronutrient Levels

Addressing Urban Healthcare Overcrowding: Stakeholder Insights

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.